Approved for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is indicated: in combination with lazertinib for first-line treatment of adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations; in combination with carboplatin and pemetrexed for adults with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21…
Loading full data from Know Your Drugs Institute…